WFDC2 and ovarian carcinoma: Our study found that the recurrence of ascites from ovarian cancer patients might be inhibited after chemotherapy, including in patients who recurred, in whom both the total amount of ascites and ascitic HE4 levels were significantly lower than those values of the no chemotherapy group.